SCHEMBL13508573

SCHEMBL13508573

CCCCN(C)S(=O)(=O)c1ccc(C(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.50
TDP1 Q9NUW8 2/20 0.46
MAPT P10636 1/20 0.44
VCAM1 P19320 2/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
CNR1 P21554 3/20 0.42
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ESR1 P03372 1/20 0.41
CCR5 P51681 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14132730 0.90 CNR2 (0.46) CNR2MAPTHTR2AHTR2CCNR1
SCHEMBL13318156 0.86 CCR5 (0.54) CNR2TDP1MAPTVCAM1POLB
SCHEMBL10784693 0.83 PSEN1 (0.53) CNR2TDP1MAPTVCAM1LMNA
SCHEMBL14132585 0.82 KMT2A (0.51) CNR2HTR2AHTR2CCNR1KDM4E
SCHEMBL12169294 0.81 LMNA (0.52) CNR2TDP1MAPTPOLBLMNA
SCHEMBL20314702 0.80 MMP3 (0.46) CNR2TDP1MAPTHTR2AHTR2C
SCHEMBL20245336 0.80 SIGMAR1 (0.56) TDP1MAPTVCAM1KDM4ELMNA
SCHEMBL10282896 0.80 TDP1 (0.49) TDP1MAPTVCAM1HTR2AHTR2C
SCHEMBL20245163 0.80 KMT2A (0.54) CNR2TDP1MAPTPOLBKDM4E
SCHEMBL19563417 0.80 SIGMAR1 (0.56) TDP1MAPTVCAM1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626111-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-04-21 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
US-8324207-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-7659268-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-02-09 US disclosed
US-20080019915-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis VERTEX PHARMACEUTICALS INCORPORATED 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 CNR2 1564/4885TDP1 4358/4885MAPT 4483/4885
US-20080019915-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis CFTR, ABCC8, ABCB1 CNR2 1221/4885TDP1 2181/4885MAPT 4668/4885
US-10626111-B2 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 CNR2 1628/4885TDP1 4439/4885MAPT 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.